Zhu D, Shen Z, Liu J, Chen J, Liu Y, Hu C, Li Z, Li Y
The Truth Emerges On July 29, 2025, Novo issued a press release and held a conference call lowering its sales and profit outlook for 2025, citing "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." Management also noted that despite the expiry of the FDA grace period for mass compounding on May 22, 2025, company research showed that unsafe and unlawful mass compounding continued
Cobalequin is an easy-to-administer form of cobalamin supplementation
Research intent is handled by the research peptide and what-is pages
Xu Y, Jiang W, Chen G, Zhu W, Ding W, Ge Z, Tan Y, Ma T, Cui G